Last reviewed · How we verify
Lopinavir/Ritonavir + 2 NRTIs
Lopinavir/Ritonavir + 2 NRTIs is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for HIV-1 infection (treatment).
Lopinavir/ritonavir inhibits HIV protease to prevent viral maturation, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block viral RNA replication.
Lopinavir/ritonavir inhibits HIV protease to prevent viral maturation, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block viral RNA replication. Used for HIV-1 infection (treatment).
At a glance
| Generic name | Lopinavir/Ritonavir + 2 NRTIs |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Lopinavir is a protease inhibitor that blocks the HIV protease enzyme, preventing the cleavage of viral polyproteins necessary for infectious particle formation. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing lopinavir plasma concentrations. The two NRTIs work synergistically by inhibiting reverse transcriptase, blocking conversion of viral RNA to DNA and preventing integration into the host genome.
Approved indications
- HIV-1 infection (treatment)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Lipid abnormalities (elevated cholesterol/triglycerides)
- Hepatotoxicity
- Hyperglycemia
- Lipodystrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r (PHASE4)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopinavir/Ritonavir + 2 NRTIs CI brief — competitive landscape report
- Lopinavir/Ritonavir + 2 NRTIs updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Lopinavir/Ritonavir + 2 NRTIs
What is Lopinavir/Ritonavir + 2 NRTIs?
How does Lopinavir/Ritonavir + 2 NRTIs work?
What is Lopinavir/Ritonavir + 2 NRTIs used for?
Who makes Lopinavir/Ritonavir + 2 NRTIs?
What drug class is Lopinavir/Ritonavir + 2 NRTIs in?
What development phase is Lopinavir/Ritonavir + 2 NRTIs in?
What are the side effects of Lopinavir/Ritonavir + 2 NRTIs?
What does Lopinavir/Ritonavir + 2 NRTIs target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (treatment)